Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 8/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 8/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL180407 | 0.98 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Bromide SCHEMBL28009101 | 0.96 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Bromide SCHEMBL9702931 | 0.86 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12814059 | 0.77 | MAPT (0.52) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29553211 | 0.77 | MAPT (0.52) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL28520045 | 0.77 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL25001636 | 0.74 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL31330119 | 0.74 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL22977483 | 0.74 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL22025603 | 0.74 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119549119-A | Modified graphene adsorbent and preparation process thereof | 扬州工业职业技术学院 | 2025-03-04 | — | — | CN | claimed |
| CN-112390762-A | Preparation method of brimonidine intermediate | 鲁南制药集团股份有限公司 | 2021-02-23 | — | — | CN | claimed |
| EP-2691377-A1 | AMINOQUINOXALINE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2014-02-05 | — | — | EP | claimed |
| WO-2012131080-A1 | AMINOQUINOXALINE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-10-04 | — | — | WO | claimed |
| CN-101318939-A | Method for preparing medicament midbody 5-bromine-6-amido quinoxaline | JIAXING INST OF APPLIED CHEMIS (CN) | 2008-12-10 | — | — | CN | claimed |
| CN-119930584-A | Brimonidine tartrate eye drops photodegradation impurity and quality detection method of brimonidine tartrate eye drops | 四川智强医药科技开发有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119549119-A | Modified graphene adsorbent and preparation process thereof | 扬州工业职业技术学院 | 2025-03-04 | — | — | CN | disclosed |
| CN-119549119-A | Modified graphene adsorbent and preparation process thereof | 扬州工业职业技术学院 | 2025-03-04 | — | — | CN | disclosed |
| CN-119462529-A | Method for synthesizing quinazoline diketone compound | 广西师范大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-115697993-B | Pyrimidine compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118791426-A | (R) -glutarimide CRBN ligands and methods of use | 百济神州有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-1993013771-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN, INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5204347-A | Reduction in intraocular pressure; increase renal flow; alteration in the rate of fluid transport in the gastrointestinal tract | ALLERGAN, INC. (US) | 1993-04-20 | — | — | US | disclosed |
| WO-1992013855-A1 | (2-IMIDAZOLIN-2-YLAMINO) TETRAHYDROQUINOLAXINES AND METHODS FOR USING SAME | ALLERGAN, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| US-5130441-A | Reaction of an imidazoline sulfonic acid with an amine in the presence of an alcohol | ALLERGAN, INC. (US) | 1992-07-14 | — | — | US | disclosed |
| US-5077292-A | Gastrointestinal disordes; kidney and vision defects | ALLERGAN, INC. (US) | 1991-12-31 | — | — | US | disclosed |
| US-5021416-A | Glaucoma | ALLERGAN, INC. (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0426390-A2 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | ALLERGAN, INC. (US) | 1991-05-08 | — | — | EP | disclosed |
| EP-0422878-A1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN, INC. (US) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | ADRA2A 4591/4885ADRA2B 4290/4885ADRA2C 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.